Metoprolol Ratiopharm (Metoprolol Succinate)

Metoprolol Ratiopharm is a selective β1‑adrenergic blocker indicated for several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain.
• Heart failure (reduced ejection fraction): improves survival and reduces hospitalisation by lowering heart rate and workload.
• Post‑myocardial infarction: reduces the risk of recurrent infarction and mortality.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other tachyarrhythmias.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and cardiac output, leading to lower blood pressure and decreased myocardial oxygen consumption, while preserving β2‑mediated bronchial and vascular effects.

Metoprolol Ratiopharm may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Bradycardia (slow heart rate)
• Cold extremities
• Gastrointestinal upset (nausea, abdominal discomfort)
• Headache

Serious or Rare Side Effects

• Severe bradycardia or heart block
• Marked hypotension
• Bronchospasm in susceptible individuals
• Depression or mood changes
• Hepatic dysfunction or elevated liver enzymes
• Worsening heart failure symptoms

Before initiating therapy, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control and avoid hypotension.
• Cardiac function assessment: evaluate ejection fraction and heart rate.
• Concomitant beta‑blocker review: avoid duplicate therapy.
• Dose adjustment in renal or hepatic impairment: start low and titrate cautiously.
• Discontinuation warning: taper gradually to prevent rebound hypertension or tachycardia.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Metoprolol succinate can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Verapamil or diltiazem: additive negative chronotropic effect may cause severe bradycardia.
• Clonidine withdrawal: abrupt stop can precipitate hypertensive crisis.
• Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.
• Amiodarone: increases plasma levels of metoprolol, raising risk of toxicity.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (other than verapamil/diltiazem): may require dose adjustment.
• ACE inhibitors or ARBs: monitor for additive blood pressure lowering.
• Diuretics: watch for electrolyte disturbances and hypotension.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine): may increase metoprolol concentrations via CYP2D6 inhibition.
• Antidepressants (e.g., tricyclics): monitor for additive cardiac effects.